Mihael Hristos Polymeropoulos Sells 156,235 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos sold 156,235 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $8.17, for a total transaction of $1,276,439.95. Following the completion of the sale, the chief executive officer directly owned 2,704,496 shares in the company, valued at $22,095,732.32. This represents a 5.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Vanda Pharmaceuticals Trading Down 3.5%

Shares of NASDAQ VNDA opened at $7.91 on Friday. Vanda Pharmaceuticals Inc. has a 1 year low of $3.81 and a 1 year high of $9.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.39 and a quick ratio of 2.38. The firm has a 50-day moving average of $7.58 and a 200 day moving average of $5.99. The stock has a market cap of $467.56 million, a P/E ratio of -2.12 and a beta of 0.55.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%.The business had revenue of $57.22 million during the quarter, compared to analysts’ expectations of $59.28 million. As a group, sell-side analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on VNDA. Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, January 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, December 17th. Wall Street Zen cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. HC Wainwright increased their price target on shares of Vanda Pharmaceuticals from $22.00 to $24.00 and gave the company a “buy” rating in a report on Monday, February 23rd. Finally, Truist Financial assumed coverage on shares of Vanda Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $18.00 price target for the company. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $14.90.

Vanda Pharmaceuticals News Summary

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Truist initiated coverage with a “Buy” and an $18 price target (roughly double current levels), a prominent bullish read that can attract buyers and trading volume. Truist starts Vanda at Buy $18 (Benzinga)
• Positive Sentiment: HC Wainwright reiterated a Buy and published detailed 2027 quarterly EPS forecasts plus a $24 price target — another high upside projection that supports constructive sentiment among growth/biotech investors. HC Wainwright issues estimates, Buy $24 PT
• Positive Sentiment: Regulatory procedure win: the FDA granted a formal evidentiary public hearing on the CDER refusal for Vanda’s sNDA for HETLIOZ in jet‑lag disorder — an uncommon, high‑visibility forum that could improve approval odds if Vanda presents a strong case. Vanda Announces FDA Grants Landmark Hearing for HETLIOZ (PR Newswire)
• Neutral Sentiment: Analyst landscape is mixed: several firms maintain Buy/Overweight calls and high targets (average ~$14.90), but ratings are not unanimous — constructive overall but not a consensus blowout. MarketBeat analyst summary
• Neutral Sentiment: HC Wainwright’s EPS cadence (quarterly 2027 estimates) gives a clearer path for modeling cash burn and potential milestones, useful for valuation but not an immediate catalyst by itself. HC Wainwright research note (MarketBeat)
• Negative Sentiment: Coordinated insider selling: CEO Mihael Polymeropoulos, CFO Kevin Moran, CMO Joakim Wijkstrom and multiple SVPs disclosed substantial sales on/around March 2 (combined proceeds in the low‑millions), which often pressures shares and triggers investor concern about insiders reducing exposure. Vanda’s Top Brass Quietly Unload a Wave of Shares (TipRanks)
• Negative Sentiment: SEC filings now formalize the insider transactions (individual ownership reductions 5–10% for some officers), removing ambiguity about size and timing and increasing short‑term selling pressure as investors parse motives (tax planning vs. signal). SEC filing — CEO ownership disclosure

Institutional Trading of Vanda Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Stonepine Capital Management LLC boosted its holdings in Vanda Pharmaceuticals by 611.3% in the second quarter. Stonepine Capital Management LLC now owns 250,000 shares of the biopharmaceutical company’s stock worth $1,180,000 after purchasing an additional 214,852 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in shares of Vanda Pharmaceuticals by 96.5% during the 2nd quarter. Squarepoint Ops LLC now owns 153,345 shares of the biopharmaceutical company’s stock valued at $724,000 after buying an additional 75,295 shares during the period. Inscription Capital LLC boosted its stake in shares of Vanda Pharmaceuticals by 293.5% in the 4th quarter. Inscription Capital LLC now owns 63,878 shares of the biopharmaceutical company’s stock worth $563,000 after buying an additional 47,646 shares during the last quarter. Martingale Asset Management L P grew its holdings in shares of Vanda Pharmaceuticals by 87.3% in the fourth quarter. Martingale Asset Management L P now owns 33,114 shares of the biopharmaceutical company’s stock worth $292,000 after acquiring an additional 15,431 shares during the period. Finally, AIGH Capital Management LLC purchased a new stake in Vanda Pharmaceuticals during the fourth quarter valued at $17,626,000. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.